Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...
Integral membrane proteins carry out essential functions in the cell, and their activities are often modulated by specific protein-lipid interactions in the membrane. Here, we elucidate the intricate ...
GET MORE AI-GENERATED SIGNALS: January 15, 2025, 11:02 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...
TD Cowen cut shares of Galapagos (NASDAQ:GLPG – Free Report) from a strong-buy rating to a strong sell rating in a report released on Thursday,Zacks.com reports. Other equities analysts also recently ...
Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Galapagos (GLPG – Research Report) today and set a price target ...
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...
U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...
Galapagos plans to split into two entities by mid-2025, focusing its core business on cell therapies while spinning off a new ...
Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...